Access to regulatory data from the European Medicines Agency: the times they are a-changing
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2046-4053
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Access to regulatory data from the European Medicines Agency: the times they are a-changing ; volume:1 ; number:1 ; day:30 ; month:10 ; year:2012 ; pages:1-4 ; date:12.2012
Systematic Reviews ; 1, Heft 1 (30.10.2012), 1-4, 12.2012
- Urheber
-
Wieseler, Beate
- Beteiligte Personen und Organisationen
- DOI
-
10.1186/2046-4053-1-50
- URN
-
urn:nbn:de:1111-201607116771
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wieseler, Beate
- McGauran, Natalie
- Kerekes, Michaela F.
- Kaiser, Thomas
- SpringerLink (Online service)
Ähnliche Objekte (12)
Establishment of the African Medicines Agency: progress, challenges and regulatory readiness
Is Medicines Parallel Trade "Regulatory Arbitrage'"?
Is medicines parallel trade ‘regulatory arbitrage’?
Regulatory roadmap for nanotechnology based medicines
Names, They Are A-Changing
Comparison of hydroxyethyl starch regulatory summaries from the Food and Drug Administration and the European Medicines Agency
Regulatory Reform Outcomes and Accelerated Regulatory Pathways for New Prescription Medicines in Australia
Agency and changing world views in Africa
Requirements for generic anti-epileptic medicines: a regulatory perspective
Review: UK medicines likely to be affected by the proposed European Medicines Agency’s guidelines on phthalates
Decisions by regulatory agencies: are they evidence-based?
Ocular medicines in children: the regulatory situation related to clinical research
Establishment of the African Medicines Agency: progress, challenges and regulatory readiness
Is Medicines Parallel Trade "Regulatory Arbitrage'"?
Is medicines parallel trade ‘regulatory arbitrage’?
Regulatory roadmap for nanotechnology based medicines
Names, They Are A-Changing
Comparison of hydroxyethyl starch regulatory summaries from the Food and Drug Administration and the European Medicines Agency
Regulatory Reform Outcomes and Accelerated Regulatory Pathways for New Prescription Medicines in Australia
Agency and changing world views in Africa
Requirements for generic anti-epileptic medicines: a regulatory perspective
Review: UK medicines likely to be affected by the proposed European Medicines Agency’s guidelines on phthalates
Decisions by regulatory agencies: are they evidence-based?
Ocular medicines in children: the regulatory situation related to clinical research
Establishment of the African Medicines Agency: progress, challenges and regulatory readiness
Is Medicines Parallel Trade "Regulatory Arbitrage'"?
Is medicines parallel trade ‘regulatory arbitrage’?
Regulatory roadmap for nanotechnology based medicines
Names, They Are A-Changing
Comparison of hydroxyethyl starch regulatory summaries from the Food and Drug Administration and the European Medicines Agency
Regulatory Reform Outcomes and Accelerated Regulatory Pathways for New Prescription Medicines in Australia
Agency and changing world views in Africa
Requirements for generic anti-epileptic medicines: a regulatory perspective
Review: UK medicines likely to be affected by the proposed European Medicines Agency’s guidelines on phthalates
Decisions by regulatory agencies: are they evidence-based?